CTMX
CytomX Therapeutics, Inc.
+0.04 (+1.63%)2.81USD1.5M成交股數612M市值–本益比(近四季)33.5股價營收比-92.4%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.4M-92% | 10.3M-80% | 663K-98% | 6.0M-76% | 18.7M-55% | 50.9M+91% | 33.4M+27% | 25.1M+2% | 41.5M | 26.6M | 26.4M | 24.7M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 17.6M | 19.2M | 21.2M | 15.3M | 13.3M | 18.9M | 21.4M | 25.2M | 22.1M | 19.4M | 16.4M | 20.7M |
| 銷售管理費用 | 7.6M | 10.7M | 7.4M | 6.4M | 6.6M | 9.4M | 8.0M | 8.4M | 7.8M | 7.8M | 6.8M | 7.4M |
| 營業利益 | −23.8M+1749% | −19.7M-187% | −27.9M-779% | −15.8M+87% | −1.3M-111% | 22.6M-3833% | 4.1M+32% | −8.5M+152% | 11.7M | −606K | 3.1M | −3.3M |
| 營業利益率 | -1,677.1% | -191.8% | -4,212.8% | -264.4% | -6.9% | 44.4% | 12.3% | -33.7% | 28.1% | -2.3% | 11.8% | -13.5% |
| 稅後淨利 | −20.7M+13319% | −18.2M-178% | −26.5M-562% | −14.2M+118% | −154K-101% | 23.5M+2711% | 5.7M+92% | −6.5M+501% | 13.8M | 837K | 3.0M | −1.1M |
| 淨利率 | -1,457.4% | -177.9% | -3,998.5% | -238.6% | -0.8% | 46.2% | 17.2% | -26.0% | 33.3% | 3.1% | 11.3% | -4.4% |
| 稀釋 EPS | – | – | – | – | – | – | – | – | – | – | – | – |
| 稀釋股數 | 219M | 177M | 138M | 165M | 129M | 87.2M | 85.2M | 84.9M | 82.6M | 73.8M | 81.0M | 66.5M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 17.2M | 28.8M | 12.7M | 34.2M | 49.0M | 47.6M | 40.6M | 43.2M | 36.2M | 17.2M | 26.0M | 57.5M |
| 應收帳款 | 37.5M | 646K | 2.0M | 1.6M | 1.9M | 2.0M | 3.4M | 2.8M | 13.2M | 3.4M | 2.4M | 1.9M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 381M | 359M | 152M | 158M | 175M | 98.5M | 139M | 159M | 185M | 202M | 221M | 209M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 79.2M | 39.4M | 52.6M | 50.9M | 55.1M | 73.4M | 162M | 190M | 216M | 249M | 272M | 294M |
| 股東權益 | 302M | 320M | 99.0M | 107M | 120M | 25.0M | −23.5M | −31.2M | −31.7M | −47.4M | −51.2M | −85.0M |
| 負債比 | 20.8% | 11.0% | 34.7% | 32.1% | 31.5% | 74.6% | 116.9% | 119.6% | 117.2% | 123.5% | 123.2% | 140.6% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −25.5M+21% | – | – | – | −21.0M | – | – | −26.0M | – | – | – |
| 資本支出 | – | 0.00 | – | – | – | 119K | – | – | 115K | – | – | – |
| 自由現金流 | – | −25.5M+21% | – | – | – | −21.2M | – | – | −26.2M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -249.1% | – | – | – | -41.6% | – | – | -63.1% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 76.2M | -44.8% | −17.4M | -22.8% | – | −75.8M |
| FY2024 | 138M | +36.4% | 31.9M | 23.1% | – | −86.5M |
| FY2023 | 101M | +90.4% | −569K | -0.6% | – | −56.9M |
| FY2022 | 53.2M | +42.5% | −99.3M | -186.8% | – | −113M |
| FY2021 | 37.3M | -45.5% | −116M | -310.5% | – | −121M |
| FY2020 | 68.4M | +154.4% | −64.8M | -94.7% | – | 3.0M |
| FY2019 | 26.9M | -54.8% | −133M | -493.7% | – | −144M |
| FY2018 | 59.5M | – | −84.6M | -142.2% | – | −79.3M |